Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone

D. S. Musgrave, P. Bosch, S. Ghivizzani, P. D. Robbins, Christopher H Evans, J. Huard

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

The need to improve bone healing permeates the discipline of orthopedic surgery. Bone morphogenetic proteins (BMPs) are capable of inducing ectopic and orthotopic bone formation. However, the ideal approach with which to deliver BMPs remains unknown. Gene therapy to deliver BMPs offers several theoretical advantages over implantation of a recombinant BMP protein, including persistent BMP delivery and eliminating the need for a foreign body carrier. A replication defective adenoviral vector was constructed to carry the rhBMP-2 gene (AdBMP-2). The direct in vivo gene therapy approach was applied in both immunodeficient and immunocompetent animals to produce intramuscular bone as early as 2 weeks following injection. Radiographic and histologic analysis revealed radiodense bone containing mature bone marrow elements. Adenovirus-mediated delivery of a marker gene (β-galactosidase) into control animals produced no bone but indicated the cells transduced with the AdBMP-2 vector. Furthermore, comparisons between immunodeficient and immunocompetent animals illustrated the magnitude and significance of the immune response. Gene therapy to deliver BMP-2 has innumerable potential clinical applications from bone defect healing to joint replacement prosthesis stabilization. This study is the first to establish the feasibility of in vivo gene therapy to deliver active BMP-2 and produce bone. Copyright (C) 1999 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)541-547
Number of pages7
JournalBone
Volume24
Issue number6
DOIs
StatePublished - Jun 1999
Externally publishedYes

Fingerprint

Bone Morphogenetic Protein 2
Bone Morphogenetic Proteins
Adenoviridae
Genetic Therapy
Bone and Bones
Replacement Arthroplasties
Galactosidases
Joint Prosthesis
Foreign Bodies
Recombinant Proteins
Osteogenesis
Genes
Orthopedics
Bone Marrow
Injections
Proteins

Keywords

  • Adenovirus
  • Bone
  • Bone morphogenetic protein (BMP)
  • Direct gene transfer
  • Gene therapy
  • Skeletal muscle

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Musgrave, D. S., Bosch, P., Ghivizzani, S., Robbins, P. D., Evans, C. H., & Huard, J. (1999). Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone, 24(6), 541-547. https://doi.org/10.1016/S8756-3282(99)00086-1

Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. / Musgrave, D. S.; Bosch, P.; Ghivizzani, S.; Robbins, P. D.; Evans, Christopher H; Huard, J.

In: Bone, Vol. 24, No. 6, 06.1999, p. 541-547.

Research output: Contribution to journalArticle

Musgrave, DS, Bosch, P, Ghivizzani, S, Robbins, PD, Evans, CH & Huard, J 1999, 'Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone', Bone, vol. 24, no. 6, pp. 541-547. https://doi.org/10.1016/S8756-3282(99)00086-1
Musgrave, D. S. ; Bosch, P. ; Ghivizzani, S. ; Robbins, P. D. ; Evans, Christopher H ; Huard, J. / Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. In: Bone. 1999 ; Vol. 24, No. 6. pp. 541-547.
@article{611e9d62a4194a57b20548df370f2ba4,
title = "Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone",
abstract = "The need to improve bone healing permeates the discipline of orthopedic surgery. Bone morphogenetic proteins (BMPs) are capable of inducing ectopic and orthotopic bone formation. However, the ideal approach with which to deliver BMPs remains unknown. Gene therapy to deliver BMPs offers several theoretical advantages over implantation of a recombinant BMP protein, including persistent BMP delivery and eliminating the need for a foreign body carrier. A replication defective adenoviral vector was constructed to carry the rhBMP-2 gene (AdBMP-2). The direct in vivo gene therapy approach was applied in both immunodeficient and immunocompetent animals to produce intramuscular bone as early as 2 weeks following injection. Radiographic and histologic analysis revealed radiodense bone containing mature bone marrow elements. Adenovirus-mediated delivery of a marker gene (β-galactosidase) into control animals produced no bone but indicated the cells transduced with the AdBMP-2 vector. Furthermore, comparisons between immunodeficient and immunocompetent animals illustrated the magnitude and significance of the immune response. Gene therapy to deliver BMP-2 has innumerable potential clinical applications from bone defect healing to joint replacement prosthesis stabilization. This study is the first to establish the feasibility of in vivo gene therapy to deliver active BMP-2 and produce bone. Copyright (C) 1999 Elsevier Science Inc.",
keywords = "Adenovirus, Bone, Bone morphogenetic protein (BMP), Direct gene transfer, Gene therapy, Skeletal muscle",
author = "Musgrave, {D. S.} and P. Bosch and S. Ghivizzani and Robbins, {P. D.} and Evans, {Christopher H} and J. Huard",
year = "1999",
month = "6",
doi = "10.1016/S8756-3282(99)00086-1",
language = "English (US)",
volume = "24",
pages = "541--547",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone

AU - Musgrave, D. S.

AU - Bosch, P.

AU - Ghivizzani, S.

AU - Robbins, P. D.

AU - Evans, Christopher H

AU - Huard, J.

PY - 1999/6

Y1 - 1999/6

N2 - The need to improve bone healing permeates the discipline of orthopedic surgery. Bone morphogenetic proteins (BMPs) are capable of inducing ectopic and orthotopic bone formation. However, the ideal approach with which to deliver BMPs remains unknown. Gene therapy to deliver BMPs offers several theoretical advantages over implantation of a recombinant BMP protein, including persistent BMP delivery and eliminating the need for a foreign body carrier. A replication defective adenoviral vector was constructed to carry the rhBMP-2 gene (AdBMP-2). The direct in vivo gene therapy approach was applied in both immunodeficient and immunocompetent animals to produce intramuscular bone as early as 2 weeks following injection. Radiographic and histologic analysis revealed radiodense bone containing mature bone marrow elements. Adenovirus-mediated delivery of a marker gene (β-galactosidase) into control animals produced no bone but indicated the cells transduced with the AdBMP-2 vector. Furthermore, comparisons between immunodeficient and immunocompetent animals illustrated the magnitude and significance of the immune response. Gene therapy to deliver BMP-2 has innumerable potential clinical applications from bone defect healing to joint replacement prosthesis stabilization. This study is the first to establish the feasibility of in vivo gene therapy to deliver active BMP-2 and produce bone. Copyright (C) 1999 Elsevier Science Inc.

AB - The need to improve bone healing permeates the discipline of orthopedic surgery. Bone morphogenetic proteins (BMPs) are capable of inducing ectopic and orthotopic bone formation. However, the ideal approach with which to deliver BMPs remains unknown. Gene therapy to deliver BMPs offers several theoretical advantages over implantation of a recombinant BMP protein, including persistent BMP delivery and eliminating the need for a foreign body carrier. A replication defective adenoviral vector was constructed to carry the rhBMP-2 gene (AdBMP-2). The direct in vivo gene therapy approach was applied in both immunodeficient and immunocompetent animals to produce intramuscular bone as early as 2 weeks following injection. Radiographic and histologic analysis revealed radiodense bone containing mature bone marrow elements. Adenovirus-mediated delivery of a marker gene (β-galactosidase) into control animals produced no bone but indicated the cells transduced with the AdBMP-2 vector. Furthermore, comparisons between immunodeficient and immunocompetent animals illustrated the magnitude and significance of the immune response. Gene therapy to deliver BMP-2 has innumerable potential clinical applications from bone defect healing to joint replacement prosthesis stabilization. This study is the first to establish the feasibility of in vivo gene therapy to deliver active BMP-2 and produce bone. Copyright (C) 1999 Elsevier Science Inc.

KW - Adenovirus

KW - Bone

KW - Bone morphogenetic protein (BMP)

KW - Direct gene transfer

KW - Gene therapy

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=0032904745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032904745&partnerID=8YFLogxK

U2 - 10.1016/S8756-3282(99)00086-1

DO - 10.1016/S8756-3282(99)00086-1

M3 - Article

VL - 24

SP - 541

EP - 547

JO - Bone

JF - Bone

SN - 8756-3282

IS - 6

ER -